

ORIGINAL RESEARCH

The role of growth differentiation factor 15 in the pathogenesis of primary myelofibrosis

Tatsuki Uchiyama¹, Hiroshi Kawabata¹, Yasuo Miura², Satoshi Yoshioka^{1,2}, Masaki Iwasa^{2,3}, Hisayuki Yao², Soichiro Sakamoto¹, Masakazu Fujimoto⁴, Hironori Haga⁴, Norimitsu Kadowaki¹, Taira Maekawa² & Akifumi Takaori-Kondo¹

¹Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

²Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan

³Division of Gastroenterology and Hematology, Shiga University of Medical Science, Otsu, Japan

⁴Department of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan

Keywords

Growth differentiation factor 15, osteoblastic differentiation, primary myelofibrosis

Correspondence

Hiroshi Kawabata, Department of Hematology/Oncology, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. Tel: +81-75-751-4964; Fax: +81-75-751-4963; E-mail: hkawabat@kuhp.kyoto-u.ac.jp

Funding Information

This work was supported in part by grant-in-aids for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (H. K., T. M., and A. T.-K.). This work was also supported by the Cell Science Research Foundation (Y. M.), and Takeda Science Foundation (Y. M.).

Received: 26 March 2015; Revised: 2 July 2015; Accepted: 3 July 2015

Abstract

Growth differentiation factor 15 (GDF15) is a pleiotropic cytokine that belongs to the transforming growth factor- β superfamily. Elevated serum concentrations of this cytokine have been reported in patients with various malignancies. To assess the potential roles of GDF15 in hematologic malignancies, we measured its serum levels in patients with these diseases. We found that serum GDF15 levels were elevated in almost all these patients, particularly in patients with primary myelofibrosis (PMF). Immunohistochemical staining of bone marrow (BM) specimens revealed that GDF15 was strongly expressed by megakaryocytes, which may be sources of increased serum GDF15 in PMF patients. Therefore, we further assessed the contribution of GDF15 to the pathogenesis of PMF. Recombinant human (rh) GDF15 enhanced the growth of human BM mesenchymal stromal cells (BM-MSCs), and it enhanced the potential of these cells to support human hematopoietic progenitor cell growth in a co-culture system. rhGDF15 enhanced the growth of human primary fibroblasts, but it did not affect their expression of profibrotic genes. rhGDF15 induced osteoblastic differentiation of BM-MSCs in vitro, and pretreatment of BM-MSCs with rGDF15 enhanced the induction of bone formation in a xenograft mouse model. These results suggest that serum levels of GDF15 in PMF are elevated, that megakaryocytes are sources of this cytokine in BM, and that GDF15 may modulate the pathogenesis of PMF by enhancing proliferation and promoting osteogenic differentiation of BM-MSCs.

doi: 10.1002/cam4.502

Introduction

Growth differentiation factor 15 (GDF15), also known as PL74, macrophage inhibitory cytokine-1 (MIC-1), placental bone morphogenetic protein (PLAB), prostate-derived factor (PDF), placental transforming growth factor- β (PTGFB), and nonsteroidal anti-inflammatory drug activated gene-1 (NAG-1), is a pleiotropic cytokine belonging to the bone morphogenetic protein (BMP) subfamily of the transforming growth factor- β (TGF- β) superfamily

[1–7]. Various types of cells express GDF15 in response to cellular stresses such as inflammation and ischemia, although its steady-state expression is almost completely restricted to the placenta [5]. In cells, GDF15 is initially translated as a 62-kD proprotein, and it is then processed by a furin-like protease to produce 25-kD mature peptides that form a disulfide-linked homodimer [8]. Specific receptors and signaling pathways for GDF15 have still not been determined; however, roles in stress responses, inflammation, tissue repair after acute injury, energy

homeostasis, systemic iron metabolism, and malignancy have been suggested [9, 10].

Serum concentrations of GDF15 increase during pregnancy as a result of strong expression in the placenta [5]. In pathological conditions, elevated serum GDF15 levels have been identified as an independent risk factor for acute coronary heart diseases [11, 12]. In addition, the serum GDF15 concentration is notably increased in patients with glioma, prostate, colorectal, or pancreatic cancers, and GDF15 was recently described as one of the 20 biomarkers that best define the malignant phenotype of numerous tumors [9, 10, 13]. However, its biological roles in cancers are complex and poorly understood; some studies have documented its protumorigenic activities, whereas others have demonstrated its antitumorigenic activities, which appear to be dependent on the types and stages of cancers [9].

In hematopoietic diseases, serum GDF15 levels are remarkably elevated in patients with dyserythropoietic disorders such as β -thalassemia, congenital dyserythropoietic anemia type I, and refractory anemia with ring sideroblasts, a subtype of myelodysplastic syndromes (MDS) [14–17]. Common features of these diseases include systemic iron overload and ineffective erythropoiesis, and the major source of the serum GDF15 in these diseases is assumed to be erythroid cells [14]. Recently, serum GDF15 levels in polycythemia vera (PV) and essential thrombocythemia (ET), which are two types of myeloproliferative neoplasm (MPN), were shown to be increased in comparison with the levels in healthy controls [18]. In addition, serum levels of GDF15 were reported to be elevated in patients with multiple myeloma (MM), and bone marrow (BM) mesenchymal stromal cells (MSCs) from these patients were shown to express high levels of GDF15 [19–22]. It was speculated that GDF15 secreted from these cells may play roles in the pathogenesis of MM by enhancing the tumor-initiation and self-renewal potential of MM cells [21].

In this study, we evaluated serum levels of GDF15 in patients with various hematologic diseases. We found that patients with primary myelofibrosis (PMF) showed very high serum GDF15 levels, which prompted us to further investigate the source of GDF15 in the BM, and to assess the contribution of GDF15 to the pathogenesis of PMF.

Materials and Methods

Reagents

Diosgenin and phorbol-13 myristate-12 acetate (PMA) were purchased from Sigma-Aldrich (St. Louis, MO). Hemin was obtained from Alfa Aesar (Ward Hill, MA).

Recombinant human growth differentiation factor 15 (rhGDF15) was purchased from R&D Systems (Minneapolis, MN). Recombinant human transforming growth factor- β 1 (rhTGF- β 1), stem cell factor (SCF), interleukin-3 (IL-3), and Flt3-ligand (Flt3-L) were purchased from Wako Pure Chemical Industries (Osaka, Japan). Thrombopoietin (TPO) was provided by Kyowa Hakko Kirin (Tokyo, Japan).

Clinical materials

Serum samples collected from 14 healthy volunteers (median age, 35 years; range, 30–46 years) and 128 adult patients with various hematologic malignancies at Kyoto University Hospital from 2006 to 2015 were used. Diagnoses of these patients were basically based on the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues [23]. Some of the patients had received chemotherapy before serum collection; however, patients in complete remission were excluded. The samples were stored at -80°C until cytokine assays were performed. The BM biopsy samples were obtained from patients with PMF and ET. As normal morphology controls, BM specimens obtained from patients with diffuse large B-cell lymphoma (DLBCL) and gastric cancer without BM involvement were used. Written informed consent for experimental use of their specimens was obtained from all the patients. This study was approved by the ethics committee of Kyoto University Graduate School and the Faculty of Medicine of Kyoto University.

Determination of serum GDF15 levels

The concentrations of GDF15 in the collected serum samples and culture supernatants were measured by enzyme-linked immunosorbent assay (ELISA) in duplicates by using a human GDF15 DuoSet ELISA Development kit (R&D Systems), according to the instructions of the manufacturer.

Detection of GDF15 protein in the BM

The BM specimens were fixed in 10% buffered formalin, processed according to conventional histological techniques, embedded in paraffin, and stained with hematoxylin and eosin. Immunohistochemical staining for GDF15 was performed using rabbit polyclonal antibodies against human GDF15 (1:100, anti-human HPA011191; Atlas Antibodies, Stockholm, Sweden) on an automated slide stainer (Ventana XT System Benchmark; Ventana Medical Systems, Tucson, AZ). Images were acquired using a BioZero BZ-8100 microscope (Keyence, Osaka, Japan).

Cell lines, culture conditions and in vitro cell differentiation and proliferation assays

HEL (JAK2 V617F positive human erythroleukemia) cells were cultured in RPMI 1640 (Nacalai Tesque, Kyoto, Japan) supplemented with 10% fetal bovine serum (FBS; Sigma-Aldrich) and 100 U/mL penicillin and 100 μ g/mL streptomycin (Nacalai Tesque) in a humidified 5% CO₂ incubator at 37°C. To induce megakaryocytic differentiation, HEL cells were grown in the presence of 10 μ mol/L diosgenin or 10 nmol/L PMA. Additionally, to induce erythroid differentiation, the cells were treated with 50 μ mol/L hemin. After 96 h of culture, approximately 3×10^4 cells were collected onto a glass slide by centrifugation for 4 min at 600g using Cytospin3 (Thermo Shandon, Pittsburgh, PA). After air-drying, the slides were stained with May-Grunwald-Giemsa (Sigma-Aldrich), and observed using light microscopy.

Hematopoietic progenitor cell expansion assay

Human bone marrow mesenchymal stromal cells (BM-MSCs) were purchased from AllCells (Emeryville, CA) and cultured in advanced-minimal essential medium (Thermo Fisher Scientific Inc., Waltham, MA) supplemented with 5% fetal bovine serum (FBS, Thermo Fisher Scientific), 100 μ mol/L ascorbic acid (Wako Pure Chemical Industries), 2 mmol/L L-glutamine, 100 U/mL penicillin, and 100 μ g/mL streptomycin (all from Gibco, Carlsbad, CA) as described previously [24–27]. Normal human BM mononuclear cells were separated from BM aspirates (AllCells) using Ficoll-Hypaque-Plus solution (GE Healthcare, Tokyo, Japan). CD34⁺HPCs (Hematopoietic progenitor cell) were isolated from BM mononuclear cells by using anti-CD34 immunomagnetic microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany). For in vitro HPC expansion assays, culture-expanded human BM-MSCs (2×10^4 cells/well) were seeded in a 24-well culture plate. Then, CD34⁺ HPCs isolated from normal human BM mononuclear cells were applied (0.6×10^3 cells/well) and co-cultured in StemSpan Serum-free Expansion Medium (SFEM; StemCell Technologies, Vancouver, Canada) supplemented with 100 ng/mL SCF, 100 ng/mL Flt3-L, 20 ng/mL IL-3, and 50 ng/mL TPO. After 10 days of co-culture, the number and surface marker expression of the expanded hematopoietic cells were determined by flow cytometry with fluorescence-conjugated antibodies. Fluorescein isothiocyanate (FITC)-conjugated anti-human CD45 and phycoerythrin (PE)-conjugated mouse anti-human CD34 antibodies were purchased from BD Pharmingen (San Diego, CA), and allophycocyanin (APC)-conjugated mouse antibody against human CD38 was purchased from Bioscience (San Diego, CA). Each analysis

included corresponding FITC- or PE-conjugated isotype controls. Dead cells were excluded by staining with propidium iodide. All data were acquired using a FACSCanto II (Becton Dickinson, San Jose, CA), and 10,000 events per sample were collected. Acquired data were subsequently analyzed with FlowJo software (Tree Star, Ashland, OR).

Culture conditions of normal human primary dermal fibroblasts

Normal human primary dermal fibroblasts (NHDF) were purchased from Lonza (Walkersville, MD) and maintained in fibroblast growth medium-2 (FGM-2) BulletKit (CC-3132, Lonza) in a humidified 5% CO₂ incubator at 37°C. For proliferation assays, NHDFs were plated at a density of 2×10^4 cells/well in 6-well plates with FGM-2 in five replicates. After 24 h of incubation, the culture medium was replaced with Dulbecco's modified Eagle's medium (DMEM, Nacalai Tesque) containing 1% FBS in the presence of 30 ng/mL rhGDF15 or 2 ng/mL rhTGF- β 1 in triplicate. Then, after an additional 48, 72, or 96 h of culture, the cells were trypsinized, resuspended, and counted in a hemocytometer by using Trypan blue exclusion. For growth inhibition assays, NHDFs were treated with either 1 μ g/mL anti-GDF15 neutralizing mAb (clone 147627, MAB957, R&D Systems) or the same concentration of control isotype-matched mouse IgG [28]. For gene expression analysis, NHDF cells were treated with 50 ng/mL rhGDF15 or 2 ng/mL rhTGF- β 1 in serum-free DMEM for 3 days.

Evaluation of proliferation and differentiation of human BM-MSCs in vitro

Human BM-MSCs that had just been thawed were seeded at a density of 2×10^4 cells/well in 6-well plates with the medium in five replicates. After 24 h of incubation, the cell culture medium was replaced with MSC growth medium with or without rhGDF15 (30 ng/mL). Adherent cells were detached from the culture dish and viable cells were counted using Trypan blue exclusion after 96, 144, and 192 h without changing the medium.

To analyze the osteogenic differentiation of human BM-MSCs, the cells were seeded at a density of 2×10^5 cells in 8 mL of the medium per 10-cm dish until confluent. The cells were then treated with 30 ng/mL rhGDF15 in the medium, which was replaced every 3–4 days. After 4 weeks of culture, the cells were washed with PBS, fixed in 60% isopropanol, and stained for mineralized deposition with 1% Alizarin Red S dye. The area of the mineralized deposits was quantified using ImageJ software (National Institutes of Health, Bethesda, MD). To analyze adipogenic differentiation, the lipid droplets in the cells

were stained with Oil Red O after 2 weeks of culture in MSC growth medium in the presence or absence of 30 ng/mL rhGDF15.

In vivo bone formation assays

In vivo bone formation assays were performed as previously described [29, 30]. In brief, a 100- μ L cell suspension containing approximately 1×10^6 BM-MSCs was seeded on a hydroxyapatite-poly D, L-lactic-co-glycolic acid composite block type scaffold (HA scaffold; GC Corporation, Tokyo, Japan) and cultured at 37°C in an atmosphere containing 5% CO₂ for 1 h, and the scaffold was then implanted subcutaneously into the dorsal surface of 7- to 9-week-old nonobese/severe combined immunodeficiency (NOD/SCID) mice. At 10 weeks after implantation, the scaffold was harvested and histological analysis was performed. The area of formed bone in five different fields viewed at $\times 100$ magnification was quantified using ImageJ software as previously described [30]. The results are expressed as the ratio of the total bone formation area to the total implant area. All mice were maintained under specific pathogen-free conditions at the Institute of Laboratory Animals, Kyoto University. The animal experiments were approved by the Committee on Animal Research of Kyoto University.

Immunoblotting analysis

Cell extracts were prepared using Mammalian Protein Extraction Reagent (M-PER; Thermo Fisher Scientific) with complete protease inhibitor cocktail (Thermo Fisher Scientific) according to the manufacturer's instructions. Western blotting was performed by standard methods with anti-phospho p42/p44 MAPK (ERK1/2) (Thr202/Tyr204) (Cell Signaling Technology Inc., Danvers, MA), anti-total ERK1/2, anti-Runx2 (1:1000, ab76956, Abcam, Cambridge, MA), anti-Osterix (SP7) (1:1000, ab22552, Abcam), and anti- β -actin (1:1000, A5441, Sigma-Aldrich) antibodies.

Quantitative real-time PCR analysis

Total RNA was extracted using TRIzol (Thermo Fisher Scientific) and reverse-transcribed into cDNA by using PrimeScript RT Master Mix (Takara Bio, Shiga, Japan), according to the manufacturer's instructions. Real-time PCR was performed with SYBR Premix Ex Taq II (Takara Bio) and with a Thermal Cycler Dice Real Time System TP850 (Takara Bio). The primer sequences used are listed in Supplementary Table S1. The gene expression data were normalized against those of β -actin. Each experiment was performed in triplicate cultures, and results were averaged.

Statistical analyses

Unpaired Student's *t*-test or Fisher's exact test was used for analyses. Data in bar graphs indicate the mean $\pm$ SE ($n = 3$), and all experiments were performed in triplicates or duplicates and repeated at least three times. Statistical significance is expressed as follows: ***P* < 0.01; **P* < 0.05; n.s., not significant.

Results

Serum GDF15 levels are remarkably elevated in patients with primary myelofibrosis

We measured the serum levels of GDF15 in 14 healthy volunteers and in 128 patients with various hematopoietic malignancies, including acute myeloid leukemia (AML; $n = 7$), MDS ($n = 28$), chronic myelogenous leukemia (CML, $n = 4$), PMF ($n = 13$), PV ($n = 22$), ET ($n = 20$), MM ($n = 10$), malignant lymphoma (ML; $n = 14$), acute lymphoblastic leukemia (ALL; $n = 3$), and adult T-cell leukemia (ATL; $n = 7$). The median serum GDF15 levels in all these disease categories were significantly elevated relative to the levels in healthy controls: AML, 4078 pg/mL; MDS, 3249 pg/mL; CML, 1393 pg/mL; PMF, 5425 pg/mL; PV, 2458 pg/mL; ET, 2732 pg/mL; MM, 2074 pg/mL; ML, 2197 pg/mL; ALL, 1780 pg/mL; ATL, 2213 pg/mL; and healthy controls, 505 pg/mL (Fig. 1). Among these patients, we noticed that the levels of serum GDF15 were remarkably high in those with PMF, a subtype of MPN, and the levels were significantly higher than the levels of the other types of MPN. PMF patients with advanced disease with more severe anemia tended to show higher serum GDF15 levels (Table S2). Therefore, in the subsequent experiments, we focused on the roles of GDF15 in the pathogenesis of PMF.

Expression of GDF15 protein in BM predominantly occurs in megakaryocytes

Previous studies have shown that GDF15 is produced by erythroid cells, macrophages, and MSCs among cell populations in the BM [4, 14, 20–22]. To investigate the source of elevated serum GDF15 in patients with PMF, we examined GDF15 protein expression in paraffin-embedded BM biopsy specimens. Microscopic examination of hematoxylin and eosin-stained specimens of patients with PMF showed increased numbers of megakaryocytes (Fig. 2A). Immunohistochemistry (IHC) revealed that GDF15 was expressed predominantly in these megakaryocytes (Fig. 2B and C). Apart from these megakaryocytes, which were clearly distinguishable owing to their large sizes, much smaller GDF15-positive cells with round or spindle shape were also observed




Figure 1. Serum Growth differentiation factor 15 (GDF15) levels in patients with various hematological malignancies. Serum concentrations of GDF15 were measured by ELISA in 14 normal subjects and 128 patients with various hematopoietic malignancies. Each individual sample was assayed in duplicate. The box and central bars show interquartile ranges and medians, whereas whiskers on bars above and below the boxes indicate the 90th and 10th percentiles. * $P < 0.05$; ** $P < 0.01$. Asterisks above the bars indicate significant increases in comparison with normal subjects. AML, acute myelogenous leukemia; MDS, myelodysplastic syndromes; CML, chronic myelogenous leukemia; PMF, primary myelofibrosis; PV, polycythemia vera; ET, essential thrombocythemia; MM, multiple myeloma; ML, malignant lymphoma; ALL, acute lymphoblastic leukemia; ATL, adult T-cell leukemia/lymphoma.

sporadically (Fig. 2C and D). Strong GDF15 expression in megakaryocytes was also observed in specimens of patients with ET (Fig. 2E) and specimens of patients with DLBCL without BM involvement (Fig. 2F). Similar findings were observed in nondecalified BM clot sections from patients with ET and localized gastric cancer without BM involvement (Fig. S1).

GDF15 is upregulated during megakaryocytic differentiation of HEL cells

Proliferation of megakaryocytes in the BM is one of the characteristic features of PMF. To investigate the

expression of GDF15 in megakaryocytic cells in vitro, we used a human erythroleukemia cell line, HEL. This cell line differentiates toward the megakaryocytic lineage in response to diosgenin or PMA, and it differentiates toward the erythroid lineage in response to hemin [31–33]. Consistent with megakaryocytic differentiation, the cell size increased, some of the cells were multinucleated (Fig. 3A–D), and cell surface expression of CD235 decreased (Fig. S2) after 144 h of incubation with diosgenin or PMA. Cell surface expression of CD41, a megakaryocytic marker, slightly increased after incubation with diosgenin, and it clearly increased after incubation with PMA (Fig. S2).




Figure 2. Histological examination of Growth differentiation factor 15 (GDF15) expression in bone marrow (BM) specimens. (A) Hematoxylin and eosin staining and (B–F) immunohistochemical staining for GDF15. (A–D) BM biopsy specimens from patients with primary myelofibrosis and (E) essential thrombocythemia. (F) A BM biopsy specimen with normal morphology obtained from a patient with diffuse large B-cell lymphoma without BM involvement. Original magnification, (A and B) $\times 100$; (C, E, and F) $\times 400$; (D) $\times 1000$.

We examined GDF15 mRNA expression and protein secretion during HEL cell differentiation. Quantitative real-time PCR revealed that GDF15 mRNA expression was significantly upregulated during diosgenin-induced differentiation toward the megakaryocytic lineage in comparison with untreated HEL cells (Fig. 3E). Furthermore, the GDF15 concentration in the culture medium of diosgenin-stimulated HEL cells significantly and progressively increased from 120 to 144 h relative to that in the culture medium of unstimulated cells (Fig. 3F). Similar results were obtained when we used PMA to induce megakaryocytic differentiation in these cells (Fig. 3G). In contrast, the amount of GDF15 in the culture supernatants of HEL cells differentiated toward the erythroid lineage by hemin decreased on a per-cell basis as a result of an increase in cell number (Fig. 3H). These results indicate that megakaryocytic HEL cells are able to synthesize GDF15.

GDF15 enhances the capacity of BM-MSCs to support HPC proliferation

Because GDF15 has been recognized as a stress cytokine that protects cells and tissues from various cellular stresses and has been reported to support the growth of various types of cells, we hypothesized that in PMF, GDF15 is produced to rescue the impaired BM environment to support hematopoiesis [9, 10]. To test this hypothesis, we examined the effect of rhGDF15 on the proliferation and differentiation of HPCs. As previously reported, $CD34^+$ HPCs from human BM cannot efficiently proliferate in the absence of feeder cells, but they proliferate in the presence of human BM-MSCs as feeder cells [26, 34, 35]. In the absence of these feeder cells, GDF15 did not support proliferation of HPCs, but rather suppressed their growth (Fig. 4A upper panel, B). Next, we treated BM-MSCs with 30 ng/mL




Figure 3. Expression of Growth differentiation factor 15 (GDF15) during megakaryocytic differentiation of HEL cells. (A–D) May-Grunwald-Giemsa staining (original magnification, $\times 400$). HEL cells were cultured in the presence of (A) control solvent, (B) 10 $\mu\text{mol/L}$ diosgenin, (C) 10 nmol/L PMA, or (D) 50 $\mu\text{mol/L}$ hemin for 96 h. (E) Expression of GDF15 mRNA in HEL cells during megakaryocytic differentiation by diosgenin. Cells were treated with 10 $\mu\text{mol/L}$ diosgenin for 48, 72, 96, 120, and 144 h, and GDF15 mRNA levels were measured by quantitative real-time PCR. The relative expression level of GDF15 was normalized to that of $\beta\text{-actin}$ and is shown relative to the expression levels of the control. (F–H) GDF15 protein secretion levels in the culture supernatant determined by ELISA. HEL cells were cultured in the presence of (F) 10 $\mu\text{mol/L}$ diosgenin for 24, 48, 72, 96, 120, and 144 h, (G) 10 nmol/L PMA for 96 h, or (H) 50 $\mu\text{mol/L}$ hemin for 96 h. Values represent the mean fold change compared to the respective control from triplicate experiments $\pm$ SE ($n = 3$). * $P < 0.05$ versus control; ** $P < 0.01$ versus control.

rhGDF15 for 3 days and used these cells as feeder cells in a direct contact co-culture system with HPCs. After 10 days of co-culture, adherent and nonadherent cells were collected, and the number of the cells was calculated using flow cytometry and a cell counter (Fig. 4A lower panel). $\text{CD}45^+$ total hematopoietic cells expanded more effectively when co-cultured with GDF15-pretreated human BM-MSCs than when co-cultured

with untreated human BM-MSCs (Fig. 4C). However, the ratios of total $\text{CD}45^+\text{CD}34^+$ HPCs, $\text{CD}45^+\text{CD}34^+\text{CD}38^-$ immature HPCs and $\text{CD}45^+\text{CD}34^+\text{CD}38^+$ less immature HPCs among the total $\text{CD}45^+$ cells were unchanged (Fig. 4D). Taken together, these results indicate that GDF15-pretreated BM-MSCs possess the potential to support the proliferation of HSCs without affecting differentiation.





Figure 4. Effect of Growth differentiation factor 15 (GDF15) treatment of human BM-MSCs on expansion of HPCs. (A) Schematic representation of the experimental procedure used to analyze the effect of GDF15 on the proliferation of CD34⁺ HPCs cultured in the absence of human BM-MSCs as feeders (upper) and on the ability of human BM-MSCs to facilitate the expansion of CD34⁺ HPCs (lower). (B) Number of HPCs in the absence of feeder cells. HPCs were cultured in the absence or presence of 0.5, 5, and 50 ng/mL rhGDF15 for 10 days in the absence of feeder cells, and the cells were then counted in a hemocytometer by using Trypan blue exclusion. The results are presented relative to those of the untreated control. Each point signifies the mean from five replicates; bars indicate $\pm$ SE. (C) Number of total CD45⁺ hematopoietic cells expanded after 10 days of co-culture with either nonstimulated or rhGDF15 (30 ng/mL)-stimulated BM-MSCs, as determined by flow cytometry and a hemocytometer ($n = 5$). (D) Percentage of total CD45⁺CD34⁺ hematopoietic cells (left panel), and the ratios of CD38⁻ (middle panel) and CD38⁺ (right panel) cells among them, expanded after 10 d of co-culture with either nonstimulated or rhGDF15-stimulated BM-MSCs. SFEM, serum-free expansion medium. * $P < 0.05$ versus control; ** $P < 0.01$ versus control; n.s., not significant.


GDF15 promotes human fibroblast proliferation

Because the proliferation of fibroblasts in BM is one of the characteristic features of PMF, we evaluated the effect of GDF15 on fibroblasts. Normal human dermal fibroblasts

(NHDF) were incubated with either rhGDF15 or rhTGF- β 1, a well-known inducer of tissue fibrosis [36]. With the addition of either rhGDF15 or rhTGF- β 1, the number of NHDFs significantly increased relative to the number of unstimulated control cells (Fig. 5A and B). A neutralizing antibody for GDF15 significantly reduced the effect of

Figure 5. Effects of Growth differentiation factor 15 (GDF15) on normal human dermal fibroblasts (NHDFs). (A and B) Effects of rhGDF15 and rhTGF- β 1 on proliferation of NHDFs. NHDFs were cultured in the absence or presence of (A) 30 ng/mL rhGDF15 or (B) 2 ng/mL rhTGF- β 1 for 24, 48, 72, and 96 h, and the cells were counted with a hemocytometer using Trypan blue exclusion. Each point signifies the mean from five replicates; bars indicate $\pm$ SE (left panels). (A, right panels) NHDF were visualized using light microscopy after 72 h of rhGDF15 exposure (original magnification, $\times 400$). (C) Effect of an anti-GDF15 neutralizing antibody on GDF15-induced NHDF proliferation. NHDFs were treated with rhGDF15 in the absence or presence of anti-GDF15 neutralizing antibodies (1 μ g/mL) or control isotype-matched mouse IgG for 96 h, and the cells were counted with a hemocytometer. (D) Immunoblot analysis of ERK1/2 phosphorylation in NHDFs treated with either rhGDF15 (left panels) or rhTGF- β 1 (right panels) for 5, 15, and 30 min. The relative phosphorylation levels of ERK1/2 were normalized to the levels of total ERK1/2 protein and quantified using ImageJ. (E) Quantitative real-time polymerase chain reaction analysis examining extracellular matrix (ECM)-related mRNA expression in NHDFs treated with rhGDF15 or rhTGF- β 1 for 3 days. The fold of increase in each mRNA in the treated group was obtained by normalization to untreated controls. COL1A1, collagen type 1 alpha 1; COL3A1, collagen type 3 alpha 1; COL4A1, collagen type 4 alpha 1; COL7A1, collagen type 7 alpha 1; ASMA, alpha-smooth muscle actin; CTGF, connective tissue growth factor; MMP-1, matrix metalloproteinase-1; TIMP-1, tissue inhibitor of metalloproteinase-1. Values represents the mean $\pm$ SE ($n = 3$). * $P < 0.05$ versus control; ** $P < 0.01$ versus control.





rhGDF15 on the proliferation of NHDFs, whereas isotype-matched mouse IgG antibodies did not influence NHDF growth (Fig. 5C). Next, we focused on the mechanisms underlying the effect of GDF15 on NHDF proliferation. Because GDF15 is a TGF- β superfamily cytokine, we assumed that it might use the extracellular signal-regulated kinase (ERK), Akt, or Smad pathways. NHDFs were treated with either rhGDF15 or rhTGF- β 1, and ERK1/2 phosphorylation was analyzed by immunoblotting. ERK1/2 was significantly phosphorylated by stimulation with GDF15 (Fig. 5D). In contrast, the phosphorylation status of Akt remained unchanged by GDF15, and the total protein and phosphorylated-Smad3 levels were below the detection limit (data not shown). These results suggest that activation of ERK pathways may play a role in mediating the GDF15-induced proliferation of NHDFs.

Because TGF- β 1 is known to participate in the process of fibrosis and pathogenesis of fibrotic disorders by affecting extracellular matrix (ECM)-related gene expression in fibroblasts, we determined whether GDF15 might have similar effects. Consistent with the results of previous reports, rhTGF- β 1 induced mRNA expression of the profibrotic genes COL1A1, COL3A1, COL4A1, COL7A1, α -smooth muscle actin, connective tissue growth factor, and TIMP-1, and suppressed the expression of the antifibrotic MMP-1 gene in NHDFs [37–39]. In contrast, rh GDF15 had no significant effect on ECM-related gene expression in NHDFs (Fig. 5E). These results indicate that GDF15 promotes the proliferation of fibroblasts but does not affect the mRNA expression of ECM-related genes involved in the process of fibrosis.

GDF15 promotes the proliferation and osteoblastic differentiation of human BM-MSCs

Because osteosclerosis is another characteristic feature of PMF and osteoblasts are derived from BM-MSCs, we next

investigated the effects of GDF15 on the proliferation and differentiation of human BM-MSCs. In an in vitro culture system, the number of BM-MSCs significantly increased after 1 week in the presence of rhGDF15, and this effect was concentration-dependent (Fig. 6A and B). We then investigated whether GDF15 promotes the differentiation of BM-MSCs into osteoblastic lineages. Human BM-MSCs exposed to rhGDF15 for 4 weeks exhibited positive Alizarin Red S staining, indicating mineralized deposits, whereas control human BM-MSCs exhibit a lack of clear staining, indicating that GDF15 had the capacity to induce bone formation (Fig. 6C). Western blot analysis revealed that protein levels of Runx2 and osterix (OSX), representative markers of osteoblastic differentiation, were significantly elevated in rhGDF15-treated human BM-MSCs compared to control cells in this condition (Fig. 6D). Next, we examined whether GDF15 affects the adipogenic differentiation of human BM-MSCs. Cells were cultured in the presence or absence of rhGDF15 for 2 weeks and stained with Oil Red O, which reflects adipogenetic differentiation. There were no significant differences in Oil Red O staining between GDF15-treated and untreated cells (data not shown).

These in vitro results prompted us to investigate the effect of GDF15 on bone formation in a xenograft mouse model that we previously established [24, 26, 27, 29, 40, 41]. Either GDF15 pretreated or untreated human BM-MSCs were seeded on HA scaffolds and subcutaneously implanted in NOD/SCID mice. After 10 weeks of implantation, the implants were histologically examined. The percentage of bone area relative to the total area of formed connective tissues in the HA scaffolds was significantly higher in GDF15-pretreated human BM-MSC implants than in untreated BM-MSC implants (Fig. 6E). Taken together, these findings indicate that GDF15 has the potential to induce human BM-MSCs to differentiate toward the osteoblastic lineage both in vitro and in vivo.

Figure 6. Effects of GDF15 on proliferation and osteoblastic differentiation of human bone marrow-derived mesenchymal stromal cells (BM-MSC). (A) Human BM-MSCs were cultured in the absence or presence of 30 ng/mL rhGDF15 for 4, 6, and 8 days, and the cells were counted in a hemocytometer. Each point signifies the mean from five replicates; bars indicate $\pm$ SE. (B) Human BM-MSCs cultured in the presence of 0, 1, and 30 ng/mL rhGDF15 for 8 days were counted in a hemocytometer. The results are presented relative to those of untreated controls (left panel), as visualized using light microscopy (right panels, original magnification $\times 400$). Bars indicate $\pm$ SE. (C and D) GDF15-induced osteoblastic differentiation of BM-MSCs. (C) Human BM-MSCs were treated with rhGDF15 (30 ng/mL) for 4 weeks. Mineralized deposits indicated by Alizarin Red S staining were quantified using ImageJ in five different fields viewed at $\times 100$ magnification. The results are presented relative to those of untreated controls (left panel), as visualized using light microscopy (right panels; magnification, $\times 100$). (D) RUNX2 and osterix (OSX) protein expression in GDF15-treated BM-MSCs were analyzed by immunoblotting. The expression levels were normalized against β -actin protein levels and quantified using ImageJ. The results are presented relative to those of untreated controls. (E) In vivo bone formation assays. (Upper panel) Schematic representation of the experimental procedure used to analyze the effects of GDF15 on bone formation in a xenograft mouse model. Human BM-MSCs treated with rhGDF15 (30 ng/mL) for 3 days were subcutaneously transplanted into NOD/SCID mice ($n = 4$) using a hydroxyapatite-poly D, L-lactic-co-glycolic acid composite block type scaffold (HA scaffold) as a carrier and harvested 10 weeks later. (Lower right and left panels) Representative microscopic images and quantitative measurement of bone formation areas in sections of human BM-MSC implants stained with hematoxylin and eosin. HA, hydroxyapatite; B, bone. Bar = 50 μ m. The results are expressed as the ratio of the total bone area to the total implant area, quantified using ImageJ in five different fields viewed at $\times 100$ magnification (lower middle panel). Bars indicate $\pm$ SE. * $P < 0.05$; ** $P < 0.01$.

Discussion

In this study, we demonstrated that the concentration of serum GDF15 was significantly increased in patients with various hematologic malignancies in comparison with healthy controls. These results were consistent with those of previous reports showing elevated levels of serum GDF15 in PV, ET, and MM patients [18, 19]. Among the hematologic diseases that we evaluated, PMF showed particularly high serum GDF15 concentrations.

PMF, the most severe type of *BCR-ABL1*-negative MPN, is characterized by sustained proliferation of abnormal megakaryocytes, BM fibrosis, osteosclerosis, extramedullary hematopoiesis, splenomegaly, and anemia. These symptoms are progressive, and some patients eventually develop acute leukemia. The prognosis of patients with this disease is generally unfavorable [42]. Blood cells of half of the patients carry *JAK2 V617F* mutant alleles, whereas mutant *MPL* genes are less common [43]. Clonal expansion of abnormal megakaryocytes and stromal reactions caused by humoral factors released from these megakaryocytes, such as TGF- β , basic fibroblast growth factor (bFGF), and platelet-derived growth factor (PDGF), have been implicated in the pathogenesis of BM fibrosis in PMF [44]. In addition, expression of BMPs, including BMP1, BMP6, and BMP7, is elevated in patients in the advanced stages of PMF, and megakaryocytes and BM-MSCs are considered to be the major sources of BMPs [45]. In particular, enhanced expression of BMP6 was observed in the prefibrotic stage of PMF and was shown to be critical in the fibrotic switch from early to more advanced stages of PMF [45].

Among the cell types in BM, erythroid progenitors, macrophages, and MSCs have been shown to produce GDF15 [14, 21]. In addition, our results for IHC staining indicated that megakaryocytes may be another source of GDF15 in BM. The possibility that megakaryocytes absorbed GDF15 from their environment and simply stored it in their cytoplasm could not be excluded; however, our in vitro HEL cell differentiation assay showed that megakaryocytic cells produced GDF15. The remarkably elevated serum concentrations of GDF15 in PMF patients observed in our study agree with the increased number of megakaryocytes observed in PMF.

GDF15 is regarded as a stress cytokine that protects cells from various types of damage such as hypoxia. Therefore, we initially hypothesized that in PMF, GDF15 is produced in response to impairment of the hematopoietic environment in BM to support hematopoiesis. Consistent with this hypothesis, human HPCs were more effectively expanded when co-cultured with human BM-MSCs that had been pretreated with GDF15 than when co-cultured with untreated BM-MSCs. Early-stage

osteoblastic cells with high expression of Runx2 have been shown to possess strong potential to support HPC proliferation [46]. The GDF15-induced osteoblastic differentiation that we showed in this study may thus enhance the hematopoiesis-supporting potential of human BM-MSCs.

Increased fibrous connective tissue levels, one of the characteristic features in PMF, are mainly caused by increased production of ECM including collagen and α -smooth muscle actin (α SMA). The amount of ECM is determined by not only the production of these fibrotic molecules but also the production of MMPs that dissolve the ECM and TIMPs that inhibit the activity of MMPs [47]. Several studies have shown that TGF- β secreted from abnormal megakaryocytes activates fibroblasts, promotes ECM deposition, suppresses production of MMPs, and leads to BM fibrosis in PMF [39, 48]. Similarly, PDGF and bFGF have also been implicated in BM fibrosis through proliferation of fibroblasts and stromal cells and have been shown to support vascular endothelial cell growth [49]. The results of this study demonstrated that GDF15 protein is highly expressed in megakaryocytes and enhances the proliferation of both fibroblasts and MSCs; however, in contrast to TGF- β , it does not alter the expression of ECM-related genes in vitro. Recently, Lambrecht et al. did not observe differences in the development of pulmonary fibrosis between wild-type and GDF15-deficient mice [50]. Therefore, GDF15 may not play essential roles in the development of tissue fibrosis.

Osteosclerosis, a bone disorder characterized by abnormal bone thickening and increased bone mass, is another common pathological feature of PMF. Osteosclerosis occurs as a result of imbalances in bone remodeling, which is a process of bone formation by osteoblasts and bone resorption by osteoclasts. Osteoblasts are derived from mesenchymal progenitors, which are multipotent nonhematopoietic cells capable of differentiating into a variety of cell types, including osteoblasts, adipocytes, and chondrocytes, by the actions of growth factors produced locally or present in the circulation [51]. Although GDF15 belongs to the BMP family, its role in bone remodeling is controversial. Subcutaneous implantation of Chinese hamster ovary cells that expressed recombinant GDF15 was shown to induce cartilage formation and the early stages of endochondral bone formation [5]. In an in vitro experiment, GDF15 was reported to inhibit osteoclastic differentiation from RAW264.7 macrophages and BM precursors by M-CSF/RANKL in a concentration-dependent manner [52]. In contrast, hypoxia-induced overexpression of GDF15 in mice was reported to promote osteoclastic differentiation, thereby reducing bone volume [53]. Wakchoure et al. inoculated nude mice with DU-145 human prostatic cancer cells overexpressing GDF15 and observed both enhanced osteoblast differentiation and

osteoclast numbers at sites of bone metastases [54]. The results of our study indicate that exposure to very high concentrations of GDF15 induced mineral depositions and expression of the osteoblastic lineage markers *Runx2* and *osterix* in BM-MSCs in vitro and that pretreatment of human BM-MSCs with rhGDF15 enhanced bone formation in a xenograft mouse model, indicating that GDF15 has the potential to promote osteoblastic differentiation under certain conditions.

Considering that GDF15 is produced in response to cellular stress and acts to protect cells and tissues in various situations, it is likely to be produced in response to the impairment of hematopoietic environment in PMF [55, 56]. In the early (prefibrotic and hypercellular) stages of PMF, GDF15 derived from megakaryocytes may support hematopoiesis by affecting BM-MSCs as a component of the BM niche. However, our results also indicate that GDF15 promotes the differentiation of BM-MSCs toward the osteoblastic lineage under certain conditions. Therefore, in advanced (fibrotic and osteosclerotic) stages, GDF15 may contribute to the development of BM fibrosis and osteosclerosis by accelerating the growth of fibroblasts and promoting the osteoblastic differentiation of BM-MSCs (Fig. S3).

In summary, we demonstrated that serum GDF15 concentrations in patients with PMF are remarkably elevated, and in BM, GDF15 is predominantly expressed by megakaryocytes. Our in vitro and in vivo studies suggest that GDF15 may be involved in the pathogenesis of PMF by promoting osteoblastic differentiation of BM-MSCs. Further studies are needed to assess the value of GDF15 as a new biomarker for evaluating treatment response and monitoring disease progression in hematologic malignancies including PMF, and to understand the precise roles of this cytokine in the BM microenvironment in both physiological and pathological conditions.

Acknowledgments

We thank Itsuko Koyanagi (Department of Diagnostic Pathology, Kyoto University Hospital) for performing the immunohistochemical staining.

Conflict of Interest

None declared.

References

1. Bottner, M., M. Laaff, B. Schechinger, G. Rappold, K. Unsicker, and C. Suter-Crazzolara. 1999. Characterization of the rat, mouse, and human genes of growth/differentiation factor-15/macrophage inhibiting cytokine-1 (GDF-15/MIC-1). *Gene* 237:105–111.
2. Morrish, D. W., E. Linetsky, D. Bhardwaj, H. Li, J. Dakour, R. G. Marsh, et al. 1996. Identification by subtractive hybridization of a spectrum of novel and unexpected genes associated with in vitro differentiation of human cytotrophoblast cells. *Placenta* 17:431–441.
3. Hromas, R., M. Hufford, J. Sutton, D. Xu, Y. Li, and L. Lu. 1997. PLAB, a novel placental bone morphogenetic protein. *Biochim. Biophys. Acta* 1354:40–44.
4. Bootcov, M. R., A. R. Bauskin, S. M. Valenzuela, A. G. Moore, M. Bansal, X. Y. He, et al. 1997. MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF- β superfamily. *Proc. Natl. Acad. Sci. USA* 94:11514–11519.
5. Paralkar, V. M., A. L. Vail, W. A. Grasser, T. A. Brown, H. Xu, S. Vukicevic, et al. 1998. Cloning and characterization of a novel member of the transforming growth factor- β /bone morphogenetic protein family. *J. Biol. Chem.* 273:13760–13767.
6. Lawton, L. N., M. F. Bonaldo, P. C. Jelenc, L. Qiu, S. A. Baumes, R. A. Marcelino, et al. 1997. Identification of a novel member of the TGF- β superfamily highly expressed in human placenta. *Gene* 203:17–26.
7. Baek, S. J., J. M. Horowitz, and T. E. Eling. 2001. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. *J. Biol. Chem.* 276:33384–33392.
8. Fairlie, W. D., A. G. Moore, A. R. Bauskin, P. K. Russell, H. P. Zhang, and S. N. Breit. 1999. MIC-1 is a novel TGF- β superfamily cytokine associated with macrophage activation. *J. Leukoc. Biol.* 65:2–5.
9. Wang, X., S. J. Baek, and T. E. Eling. 2013. The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. *Biochem. Pharmacol.* 85:597–606.
10. Unsicker, K., B. Spittau, and K. Krieglstein. 2013. The multiple facets of the TGF- β family cytokine growth/differentiation factor-15/macrophage inhibitory cytokine-1. *Cytokine Growth Factor Rev.* 24:373–384.
11. Kempf, T., J. M. Sinning, A. Quint, C. Bickel, C. Sinning, P. S. Wild, et al. 2009. Growth-differentiation factor-15 for risk stratification in patients with stable and unstable coronary heart disease: results from the AtheroGene study. *Circ. Cardiovasc. Genet.* 2:286–292.
12. Kempf, T., S. von Haehling, T. Peter, T. Allhoff, M. Ciccoira, W. Doehner, et al. 2007. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. *J. Am. Coll. Cardiol.* 50:1054–1060.
13. Basil, C. F., Y. Zhao, K. Zavaglia, P. Jin, M. C. Panelli, S. Voiculescu, et al. 2006. Common cancer biomarkers. *Cancer Res.* 66:2953–2961.
14. Tanno, T., N. V. Bhanu, P. A. Oneal, S. H. Goh, P. Staker, Y. T. Lee, et al. 2007. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. *Nat. Med.* 13:1096–1101.

15. Tamary, H., H. Shalev, G. Perez-Avraham, M. Zoldan, I. Levi, D. W. Swinkels, et al. 2008. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. *Blood* 112:5241–5244.
16. Kawabata, H., S. Doisaki, A. Okamoto, T. Uchiyama, S. Sakamoto, A. Hama, et al. 2012. A case of congenital dyserythropoietic anemia Type 1 in a Japanese adult with a CDAN1 gene mutation and an inappropriately low serum hepcidin-25 level. *Intern. Med.* 51:917–920.
17. Ramirez, J. M., O. Schaad, S. Durual, D. Cossali, M. Docquier, P. Beris, et al. 2009. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. *Br. J. Haematol.* 144:251–262.
18. Tarkun, P., O. Mehtap, E. B. Atesoglu, A. Geduk, M. M. Musul, and A. Hacıhanefioglu. 2013. Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. *Eur. J. Haematol.* 91:228–235.
19. Tarkun, P., E. Birtas Atesoglu, O. Mehtap, M. M. Musul, and A. Hacıhanefioglu. 2013. Serum growth differentiation factor 15 levels in newly diagnosed multiple myeloma patients. *Acta Haematol.* 131:173–178.
20. Corre, J., E. Labat, N. Espagnolle, B. Hebraud, H. Avet-Loiseau, M. Roussel, et al. 2012. Bioactivity and prognostic significance of growth differentiation factor GDF15 secreted by bone marrow mesenchymal stem cells in multiple myeloma. *Cancer Res.* 72:1395–1406.
21. Tanno, T., Y. Lim, Q. Wang, M. Chesi, P. L. Bergsagel, G. Matthews, et al. 2014. Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells. *Blood* 123:725–733.
22. Corre, J., K. Mahtouk, M. Attal, M. Gadelorge, A. Huynh, S. Fleury-Cappellesso, et al. 2007. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. *Leukemia* 21:1079–1088.
23. WHO. 2008. Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon.
24. Miura, Y., M. Miura, S. Gronthos, M. R. Allen, C. Cao, T. E. Uveges, et al. 2005. Defective osteogenesis of the stromal stem cells predisposes CD18-null mice to osteoporosis. *Proc. Natl. Acad. Sci. USA* 102:14022–14027.
25. Yamaza, T., Y. Miura, K. Akiyama, Y. Bi, W. Sonoyama, S. Gronthos, et al. 2009. Mesenchymal stem cell-mediated ectopic hematopoiesis alleviates aging-related phenotype in immunocompromised mice. *Blood* 113:2595–2604.
26. Yao, H., Y. Miura, S. Yoshioka, M. Miura, Y. Hayashi, A. Tamura, et al. 2014. Parathyroid hormone enhances hematopoietic expansion via upregulation of cadherin-11 in bone marrow mesenchymal stromal cells. *Stem Cells* 32:2245–2255.
27. Yoshioka, S., Y. Miura, H. Yao, S. Satake, Y. Hayashi, A. Tamura, et al. 2014. CCAAT/enhancer-binding protein β expressed by bone marrow mesenchymal stromal cells regulates early B-cell lymphopoiesis. *Stem Cells* 32:730–740.
28. Griner, S. E., J. P. Joshi, and R. Nahta. 2013. Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion. *Biochem. Pharmacol.* 85:46–58.
29. Miura, M., Y. Miura, W. Sonoyama, T. Yamaza, S. Gronthos, and S. Shi. 2006. Bone marrow-derived mesenchymal stem cells for regenerative medicine in craniofacial region. *Oral Dis.* 12:514–522.
30. Shi, S., S. Gronthos, S. Chen, A. Reddi, C. M. Counter, P. G. Robey, et al. 2002. Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. *Nat. Biotechnol.* 20:587–591.
31. Beneytout, J. L., C. Nappez, M. J. Leboutet, and G. Malinvaud. 1995. A plant steroid, diosgenin, a new megakaryocytic differentiation inducer of HEL cells. *Biochem. Biophys. Res. Commun.* 207:398–404.
32. Long, M. W., C. H. Heffner, J. L. Williams, C. Peters, and E. V. Prochownik. 1990. Regulation of megakaryocyte phenotype in human erythroleukemia cells. *J. Clin. Invest.* 85:1072–1084.
33. Papayannopoulou, T., B. Nakamoto, S. Kurachi, and R. Nelson. 1987. Analysis of the erythroid phenotype of HEL cells: clonal variation and the effect of inducers. *Blood* 70:1764–1772.
34. McNiece, I., J. Harrington, J. Turney, J. Kellner, and E. J. Shpall. 2004. Ex vivo expansion of cord blood mononuclear cells on mesenchymal stem cells. *Cytotherapy* 6:311–317.
35. Li, N., P. Feugier, B. Serrurier, V. Latger-Cannard, J. F. Lesesve, J. F. Stoltz, et al. 2007. Human mesenchymal stem cells improve ex vivo expansion of adult human CD34+ peripheral blood progenitor cells and decrease their allostimulatory capacity. *Exp. Hematol.* 35:507–515.
36. Border, W. A., and N. A. Noble. 1994. Transforming growth factor β in tissue fibrosis. *N. Engl. J. Med.* 331:1286–1292.
37. Branton, M. H., and J. B. Kopp. 1999. TGF- β and fibrosis. *Microbes Infect.* 1:1349–1365.
38. Varga, J., and R. I. Bashey. 1995. Regulation of connective tissue synthesis in systemic sclerosis. *Int. Rev. Immunol.* 12:187–199.
39. Blobel, G. C., W. P. Schiemann, and H. F. Lodish. 2000. Role of transforming growth factor β in human disease. *N. Engl. J. Med.* 342:1350–1358.
40. Miura, M., Y. Miura, H. M. Padilla-Nash, A. A. Molinolo, B. Fu, V. Patel, et al. 2006. Accumulated chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. *Stem Cells* 24:1095–1103.
41. Yamaza, T., Y. Miura, Y. Bi, Y. Liu, K. Akiyama, W. Sonoyama, et al. 2008. Pharmacologic stem cell

- based intervention as a new approach to osteoporosis treatment in rodents. *PLoS ONE* 3:e2615.
42. Wolf, D., J. Rudzki, and G. Gastl. 2011. Current treatment concepts of Philadelphia-negative MPN. *Curr. Cancer Drug Targets* 11:44–55.
 43. Campbell, P. J., and A. R. Green. 2006. The myeloproliferative disorders. *N. Engl. J. Med.* 355:2452–2466.
 44. Hasselbalch, H. C. 2013. The role of cytokines in the initiation and progression of myelofibrosis. *Cytokine Growth Factor Rev.* 24:133–145.
 45. Bock, O., J. Hoftmann, K. Theophile, K. Hussein, B. Wiese, J. Schlue, et al. 2008. Bone morphogenetic proteins are overexpressed in the bone marrow of primary myelofibrosis and are apparently induced by fibrogenic cytokines. *Am. J. Pathol.* 172:951–960.
 46. Chitteti, B. R., Y. H. Cheng, D. A. Streicher, S. Rodriguez-Rodriguez, N. Carlesso, E. F. Srouf, et al. 2010. Osteoblast lineage cells expressing high levels of Runx2 enhance hematopoietic progenitor cell proliferation and function. *J. Cell. Biochem.* 111:284–294.
 47. Wang, J. C., A. Novetsky, C. Chen, and A. D. Novetsky. et al. 2002. Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis. *Br. J. Haematol.* 119:709–712.
 48. Martyre, M. C., N. Romquin, M. C. Le Bousse-Kerdiles, S. Chevillard, B. Benyahia, B. Dupriez, et al. 1994. Transforming growth factor- β and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. *Br. J. Haematol.* 88:9–16.
 49. Di Raimondo, F., M. P. Azzaro, G. A. Palumbo, S. Bagnato, F. Stagno, G. M. Giustolisi, et al. 2001. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. *Leukemia* 15:976–980.
 50. Lambrecht, S., V. Smith, K. De Wilde, J. Coudenys, S. Decuman, D. Deforce, et al. 2014. Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. *Arthritis Rheumatol.* 66:418–427.
 51. Pittenger, M. F., A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. Mosca, et al. 1999. Multilineage potential of adult human mesenchymal stem cells. *Science* 284:143–147.
 52. Vanhara, P., E. Lincova, A. Kozubik, P. Jurdic, K. Soucek, and J. Smarda. 2009. Growth/differentiation factor-15 inhibits differentiation into osteoclasts—a novel factor involved in control of osteoclast differentiation. *Differentiation* 78:213–222.
 53. Hinoi, E., H. Ochi, T. Takarada, E. Nakatani, T. Iezaki, H. Nakajima, et al. 2012. Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia. *J. Bone Miner. Res.* 27:938–949.
 54. Wakchoure, S., T. M. Swain, T. A. Hentunen, A. R. Bauskin, D. A. Brown, S. N. Breit, et al. 2009. Expression of macrophage inhibitory cytokine-1 in prostate cancer bone metastases induces osteoclast activation and weight loss. *Prostate* 69:652–661.
 55. Heger, J., E. Schiegnitz, D. von Waldthausen, M. M. Anwar, H. M. Piper, and G. Euler. 2010. Growth differentiation factor 15 acts anti-apoptotic and pro-hypertrophic in adult cardiomyocytes. *J. Cell. Physiol.* 224:120–126.
 56. Tanno, T., P. Noel, and J. L. Miller. 2010. Growth differentiation factor 15 in erythroid health and disease. *Curr. Opin. Hematol.* 17:184–190.

Supporting Information

Additional supporting information may be found in the online version of this article:



Figure S1. Histological examination of growth differentiation factor 15 (GDF15) expression in bone marrow (BM) clots without decalcification. (A) BM clot sections with normal morphology obtained from patients with localized gastric cancer. GDF15 is principally expressed by megakaryocytes. Original magnification, $\times 400$.

Figure S2. In vitro differentiation of HEL cells. HEL cells were cultured in the presence of 10 $\mu\text{mol/L}$ diosgenin, 50 $\mu\text{mol/L}$ hemin, or 10 nmol/L PMA for 144 h, which was followed by flow-cytometric analyses of cell surface expression of CD41 and CD235a. PE-conjugated mouse anti-human CD41 (Cosmo Bio, Tokyo, Japan) and CD235a (BD Biosciences, Franklin Lakes, NJ) antibodies were used. Shaded purple areas represent histograms of isotype of control experiments.

Figure S3. A hypothetical scheme for the roles of GDF15 in primary myelofibrosis. GDF15 may be produced in response to the impairment of hematopoietic environment. In the early prefibrotic stage, GDF15 derived from megakaryocytes may support hematopoiesis by affecting BM-MSCs as a component of the BM niche. In the fibrotic stages, however, GDF15 may contribute to the development of BM fibrosis by accelerating the growth of fibroblasts together with TGF- β -induced ECM production. In a more advanced stage, excessive or prolonged GDF15 production may lead to the development of osteosclerosis by promoting osteoblastic differentiation of BM-MSCs. PMF, primary myelofibrosis; MK, Megakaryocyte; MSC, mesenchymal stroma cell; HPC, hematopoietic progenitor cell; GDF15, growth differentiation factor 15; TGF- β transforming growth factor, β -ECM, extracellular matrix; BM, bone marrow.


Table S1. Primer sequences of the target genes used in quantitative RT-PCR.

Table S2. Clinical features of patients with myeloproliferative neoplasms.


A**B**

Supplementary Figure S1.

Histological examination of GDF15 expression in bone marrow (BM) clots without decalcification. (A) BM clot sections from patients with ET. (B) BM clot sections with normal morphology obtained from patients with localized gastric cancer. GDF15 is principally expressed by megakaryocytes. Original magnification, $\times 400$.



Supplementary Figure S2. In vitro differentiation of HEL cells. HEL cells were cultured in the presence of 10 μ M diosgenin, 50 μ M hemin, or 10 nM PMA for 144 h, which was followed by flow-cytometric analyses of cell-surface expression of CD41 and CD235a. PE-conjugated mouse anti-human CD41 (Cosmo Bio, Tokyo, Japan) and CD235a (BD Biosciences, Franklin Lakes, NJ) antibodies were used. Shaded purple areas represent histograms of isotype control experiments.



Supplementary Figure S2.

A hypothetical scheme for the roles of GDF15 in PMF. GDF15 may be produced in response to the impairment of hematopoietic environment. In the early prefibrotic stage, GDF15 derived from megakaryocytes may support hematopoiesis by affecting BM-MSCs as a component of the BM niche. In the fibrotic stages, however, GDF15 may contribute to the development of BM fibrosis by accelerating the growth of fibroblasts together with TGF- β -induced ECM production. In a more advanced stage, excessive or prolonged GDF15 production may lead to the development of osteosclerosis by promoting osteoblastic differentiation of BM-MSCs.

PMF; primary myelofibrosis; MK, megakaryocyte; MSC, mesenchymal stromal cell; HPC, hematopoietic progenitor cell; GDF15, growth differentiation factor 15; TGF- β transforming growth factor- β ; ECM, extracellular matrix; BM, bone marrow.

Supplementary Table S1.

Primer sequences of the target genes used in quantitative RT-PCR

Target gene		Primer nucleotide sequence
β -actin	(forward)	5'-AGAGCTACGAGCTGCCTGAC-3'
	(reverse)	5'-AGCACTGTGTTGGCGTACAG-3'
GDF15	(forward)	5'-CTCCAGATTCCGAGAGTTGC-3'
	(reverse)	5'-AGAGATACGCAGGTGCAGGT-3'
COL1A1	(forward)	5'-GAACGCGTGTCATCCCTTGT-3'
	(reverse)	5'-GAACGAGGTAGTCTTTCAGCAACA-3'
COL3A1	(forward)	5'-AACACGCAAGGCTGTGAGACT-3'
	(reverse)	5'-GCCAACGTCCACACCAAATT-3'
COL4A1	(forward)	5'-ACTCTTTTGTGATGCACACCA-3'
	(reverse)	5'-AAGCTGTAAGCGTTTGCGTA-3'
COL7A1	(forward)	5'-TTACGCCGCTGACATTGTGTT-3'
	(reverse)	5'-ACCAGCCCTTCGAGAAAGC-3'
ASMA	(forward)	5'-GACCGAATGCAGAAGGAGAT-3'
	(reverse)	5'-CCACCGATCCAGACAGAGTA-3'
CTGF	(forward)	5'-TTTGGCCCAGACCCAACTAT-3'
	(reverse)	5'-GTGCAGCCAGAAAGCTCAAA-3'
MMP-1	(forward)	5'-GGCCCACAAACCCCAAAG-3'
	(reverse)	5'-ATCTCTGTCTGGCAAATTCGTAAGC-3'
TIMP-1	(forward)	5'-GGGACACCAGAAGTCAACCA-3'
	(reverse)	5'-GGCTTGGAACCCTTTATACATC-3'

GDF15; growth differentiation factor 15, COL1A1; collagen type 1 alpha 1, COL3A1; collagen type 3 alpha 1, COL4A1; collagen type 4 alpha 1, COL7A1; collagen type 7 alpha 1, ASMA; alpha-smooth muscle actin, CTGF; connective tissue growth factor, MMP-1; matrix metalloproteinase-1, TIMP-1; tissue inhibitor of metalloproteinase-1

Supplementary Table S2

Clinical features of patients with myeloproliferative neoplasms

No.	Age Sex	Disease Diagnosis	duration (months)	GDF15 (pg/mL)	HGB (g/dL)	PLT (10 ⁹ /L)	WBC (10 ⁹ /L)	Spleno megaly	BM fibrosis	JAK2 V617F	Treatment
1	80 M	PMF	90	15,882	6.8	456	13.3	+++	2 or 3	N/A	6-MP
2	62 M	PMF	13	11,828	6.6	32	1.5	+++	+	+	None
3	73 F	PMF	208	10,833	4.5	107	12.5	+++	3	-	MEL
4	58 F	PMF	129	10,380	12.5	193	11.0	+++	+	-	HU
5	92 F	PMF	60	4,942	11.0	440	17.1	+++	1	+	HU
6	53 M	PMF	36	4,860	7.5	556	6.0	+++	3	+	None
7	81 F	PMF	45	4,855	9.9	62	1.0	+++	2 or 3	N/A	THAL
8	66 M	PMF	3	4,182	9.3	447	57.4	+++	2	+	None
9	62 F	PMF	2	2,618	12.6	502	33.1	+++	2	+	None
10	43 F	PMF	17	2,339	8.9	133	4.9	+++	2 or 3	-	None
11	64 F	PV	132	4,968	6.1	14	0.5	+++	N/A	N/A	irradiation
12	70 M	PV	204	3,725	4.7	99	73.6	+++	2	+	HU
13	63 M	PV	222	3,349	13.1	130	16.9	+++	N/A	+	HU
14	85 F	PV	161	2,777	10.3	259	14.3	+	N/A	+	HU
15	81 M	PV	304	2,518	14.8	98	4.9	+++	N/A	N/A	None
16	59 F	PV	60	2,458	15.2	846	8.9	+	N/A	+	None
17	52 M	PV	40	2,236	14.3	371	7.3	+	0	+	HU
18	65 M	PV	42	1,578	11.4	313	10.9	++	N/A	+	HU
19	54 M	PV	102	1,555	14.7	443	22.5	++	0	+	HU
20	67 M	PV	244	1,431	13.4	534	10.5	+	0	+	None
21	65 F	PV	51	1,365	11.7	410	31.1	N/A	0	+	None
22	65 F	PV	27	1,080	15.6	373	12.2	+	0	+	None
23	70 F	PV	73	1,048	13.9	399	9.2	+	0	+	HU
24	79 F	ET	17	4,881	15.2	846	32.2	-	N/A	+	MTX
25	88 F	ET	73	4,759	11.5	702	4.7	N/A	N/A	-	HU
26	70 M	ET	183	3,725	6.3	85	64.9	+	2	-	HU
24	79 M	ET	76	3,196	15.2	472	17.2	+	1	+	HU

27	69	M	ET	6	2,808	14.7	697	14.7	-	0	+	None
28	41	M	ET	29	1,907	12.8	884	11.1	-	N/A	+	None
29	65	F	ET	14	1,659	12.8	1260	18.0	+	1	+	None
30	71	F	ET	14	1,391	12.6	1149	9.8	-	N/A	-	None
31	58	F	ET	57	1,352	11.7	481	45.0	+	1	+	HU

BM fibrosis was graded according to European consensus on grading bone marrow fibrosis [57]. Presence of fibrosis without grading information was indicated as “+.”

Splenomegaly was graded as follows: +, mild splenomegaly, with a size smaller than that of half of the liver; ++, moderate splenomegaly, with a size larger than that of half of the liver but smaller than that of the liver; +++, severe splenomegaly with a size larger than that of the liver. Data for some cases were unavailable because of unlinked anonymization and not included in this table. Abbreviations; GDF15, growth differentiation factor 15; 6-MP, mercaptopurine; MEL, melphalan; HU, hydroxyurea; THAL, thalidomide; MTX, methotrexate; N/A, not available.